These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33846959)

  • 1. Multiple Sclerosis Patients Treated With Diroximel Fumarate in the Real-World Setting Have High Rates of Persistence and Adherence.
    Liseno J; Lager B; Miller C; Shankar SL; Mendoza JP; Lewin JB
    Neurol Ther; 2021 Jun; 10(1):349-360. PubMed ID: 33846959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis.
    Lager B; Liseno J; Božin I; England SM; Shankar SL; Mendoza JP; Lewin JB
    Neurol Ther; 2023 Feb; 12(1):145-159. PubMed ID: 36334241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study.
    Wray S; Then Bergh F; Wundes A; Arnold DL; Drulovic J; Jasinska E; Bowen JD; Negroski D; Naismith RT; Hunter SF; Gudesblatt M; Chen H; Lyons J; Shankar SL; Kapadia S; Mendoza JP; Singer BA
    Adv Ther; 2022 Apr; 39(4):1810-1831. PubMed ID: 35211872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study.
    Palte MJ; Wehr A; Tawa M; Perkin K; Leigh-Pemberton R; Hanna J; Miller C; Penner N
    Adv Ther; 2019 Nov; 36(11):3154-3165. PubMed ID: 31538304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-Related Quality of Life with Diroximel Fumarate in Patients with Relapsing Forms of Multiple Sclerosis: Findings from Qualitative Research Using Patient Interviews.
    Gudesblatt M; Roman C; Singer BA; Schmidt H; Thomas J; Shankar SL; Lyons J; Kapadia S
    Adv Ther; 2022 Jul; 39(7):3199-3213. PubMed ID: 35556227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study.
    Wundes A; Wray S; Gold R; Singer BA; Jasinska E; Ziemssen T; de Seze J; Repovic P; Chen H; Hanna J; Messer J; Miller C; Naismith RT
    Ther Adv Neurol Disord; 2021; 14():1756286421993999. PubMed ID: 33796143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.
    Naismith RT; Wundes A; Ziemssen T; Jasinska E; Freedman MS; Lembo AJ; Selmaj K; Bidollari I; Chen H; Hanna J; Leigh-Pemberton R; Lopez-Bresnahan M; Lyons J; Miller C; Rezendes D; Wolinsky JS;
    CNS Drugs; 2020 Feb; 34(2):185-196. PubMed ID: 31953790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
    Singer BA; Arnold DL; Drulovic J; Freedman MS; Gold R; Gudesblatt M; Jasinska E; LaGanke CC; Naismith RT; Negroski D; Oh J; Hernandez Perez MA; Selmaj K; Then Bergh F; Wundes A; Ziemssen T; Castro-Borrero W; Chen H; Levin S; Scaramozza M; Shankar SL; Wang T; Wray S
    Mult Scler; 2023 Dec; 29(14):1795-1807. PubMed ID: 37905526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
    Naismith RT; Wolinsky JS; Wundes A; LaGanke C; Arnold DL; Obradovic D; Freedman MS; Gudesblatt M; Ziemssen T; Kandinov B; Bidollari I; Lopez-Bresnahan M; Nangia N; Rezendes D; Yang L; Chen H; Liu S; Hanna J; Miller C; Leigh-Pemberton R
    Mult Scler; 2020 Nov; 26(13):1729-1739. PubMed ID: 31680631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability, and efficacy of diroximel fumarate in a cohort of Black patients with multiple sclerosis from the phase 3 EVOLVE-MS-1 study.
    Hunter SF; Lindsey JW; Osborne B; Schreiber B; Branco F; Levin S; Lewin JB; Scaramozza M; Tian Z; Antezana A
    Mult Scler Relat Disord; 2024 Nov; 91():105912. PubMed ID: 39393172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study.
    Araujo L; Geertsen SS; Amedume A; Higuchi K; van Wingerden J
    Neurol Ther; 2022 Dec; 11(4):1735-1748. PubMed ID: 36152222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diroximel fumarate in the treatment of multiple sclerosis.
    Jonasson E; Sejbaek T
    Neurodegener Dis Manag; 2020 Oct; 10(5):267-276. PubMed ID: 32686599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: NEDA-3 After Re-Baselining in the Phase 3 EVOLVE-MS-1 Study.
    Bowen JD; Stulc J; Hunter SF; Chen H; Lewin JB; Scaramozza M; Bozin I; Then Bergh F
    Adv Ther; 2024 Aug; 41(8):3396-3406. PubMed ID: 38878121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diroximel fumarate to treat multiple sclerosis.
    Wang Y; Bhargava P
    Drugs Today (Barc); 2020 Jul; 56(7):431-437. PubMed ID: 32648853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diroximel Fumarate as a Novel Oral Immunomodulating Therapy for Relapsing Forms of Multiple Sclerosis: A Review on the Emerging Data.
    Hauer L; Sellner J
    Drug Des Devel Ther; 2022; 16():3915-3927. PubMed ID: 36388086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-life persistence and tolerability with dimethyl fumarate.
    Sejbaek T; Nybo M; Petersen T; Illes Z
    Mult Scler Relat Disord; 2018 Aug; 24():42-46. PubMed ID: 29906666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence and discontinuation rates in patients on Tecfidera™ (dimethyl fumarate): Long-term Canadian experience from the Biogen ONE™ support program.
    Thompson MT; Virginia D; Nick B; Melissa G; Engineer N; Shen C; Reedie S
    Mult Scler Relat Disord; 2022 Nov; 67():104080. PubMed ID: 35973386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Worsening of lymphopenia in patients with multiple sclerosis when switched from dimethyl fumarate to diroximel fumarate.
    Dempsey JP; Wu L; Balshi A; Jun C; Baber U; Sloane JA
    Mult Scler Relat Disord; 2024 Sep; 89():105737. PubMed ID: 39029343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Characterization of Dimethyl Fumarate-Related Gastrointestinal Events in Multiple Sclerosis: Management Strategies to Improve Persistence on Treatment and Patient Outcomes.
    Min J; Cohan S; Alvarez E; Sloane J; Phillips JT; van der Walt A; Koulinska I; Fang F; Miller C; Chan A
    Neurol Ther; 2019 Jun; 8(1):109-119. PubMed ID: 30706431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis.
    Jiang T; Ziemssen T; Wray S; Shen C; Söderbärg K; Lewin JB; Božin I; Freedman MS
    CNS Drugs; 2023 May; 37(5):441-452. PubMed ID: 37155132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.